

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

**POLL RESULT OF THE SPECIAL GENERAL MEETING
HELD ON 29 JULY 2016**

The Board is pleased to announce that the Resolution as set out in the Notice was duly passed as an ordinary resolution of the Company by the Shareholders by way of poll at the SGM held on 29 July 2016.

Reference is made to the circular (“**Circular**”) and notice (“**Notice**”) of the special general meeting (“**SGM**”) of New Ray Medicine International Holding Limited (“**Company**”) dated 13 July 2016. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that the resolution as set out in the Notice (“**Resolution**”) was duly passed as an ordinary resolution of the Company by the Shareholders by way of poll at the SGM held on 29 July 2016.

As at the date of the SGM, the total number of the issued Shares was 347,040,000. As at the date of the SGM, Mr. Zhou Ling, an executive Director and the chairman of the Board, personally held 20,879,238 Shares, representing approximately 6.02% of the issued share capital of the Company; and Ms. Yang Fang, an executive Director and the chief executive officer of the Company and the spouse of Mr. Zhou Ling, personally held 8,552,762 Shares, representing approximately 2.46% of the issued share capital of the Company. As disclosed in the Circular, save for Mr. Zhou and Ms. Yang, and their respective associates who were required to abstain from voting on the Resolution, no other Shareholders were required to abstain from voting on the Resolution proposed at the SGM in accordance with the Listing Rules. Accordingly, as at the date of the SGM, there were a total of 317,608,000, representing 91.52% of the issued share capital of the Company, entitling the Shareholders to attend and vote for or against the Resolution at the SGM.

There were no Shareholders who were entitled to attend and vote only against the Resolution. None of the Shareholders was entitled to attend and abstain from voting in favour of the Resolution proposed at the SGM according to Rule 13.40 of the Listing Rules. None of the Shareholders has stated his/her/its intention in the Circular to vote against the Resolution or to abstain from voting at the SGM.

The full text of the Resolution was set out in the Notice. The poll result for the Resolution was as follows:

Ordinary Resolution	Number of votes (%)	
	For	Against
To approve, confirm and ratify the Acquisitions (as defined and described in the Circular) and to approve the transactions contemplated under the Agreements (as defined in the Circular) and to authorise the directors of the Company or a duly authorised committee of the board of the directors of the Company to take all such actions as they consider necessary, appropriate, desirable and expedient for the purposes of giving effect to or in connection with the Acquisitions, the Agreements and all transactions contemplated thereunder.	62,091,280 (100%)	0 (0%)

Note: The number of votes and percentage of the voting as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the SGM in person, by authorised corporate representative or by proxy.

As more than 50% of the votes were cast in favour of the Resolution, the Resolution was duly passed as an ordinary resolution of the Company by the Shareholders.

The branch share registrar and transfer office of the Company in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the SGM.

By order of the Board
New Ray Medicine International Holding Limited
LEE Chik Yuet
Executive Director

Hong Kong, 29 July 2016

As at the date of this announcement, the executive Directors are Mr. Zhou Ling, Ms. Yang Fang and Mr. Lee Chik Yuet; and the independent non-executive Directors are Mr. Ho Hau Cheung, BBS, MH, Mr. Sung Hak Keung, Andy and Mr. Leung Chi Kin.